【摘要】 目的 探究妇科肿瘤患者在采用利伐沙班所呈现出的预防抗凝作用。方法 选取2020年9月至2022年2月南通市肿瘤医院收治的妇科肿瘤患者106例开展研究。106例患者结合不同的干预措施分为两组，研究组30例，常规组76例。研究组患者应用口服利伐沙班方式进行预防性抗凝，常规组在术后做好肢体按摩并穿戴弹力袜。分析静脉血栓发生情况以及两组干预前的凝血指标差异以及研究组干预前后的凝血指标差异。结果 研究组（3.33%）静脉血栓发生率显著低于常规组（11.84%），χ~2=1.822,P=0.177。在预防干预后研究组的凝血功能指标测定结果与常规组差异有统计学意义，P <0.05。结论 针对肿瘤血栓高危患者在临床中应当积极预防抗凝，采用利伐沙班进行抗凝可以达到外源性、内源性双方面的预防抗凝作用，可以有效降低血栓发生风险。更多还原

【Abstract】 Objective To investigate the preventive anticoagulant effect of rivasabant in gynecologic tumor patients. Methods A total of 106gynecologic oncology patients admitted to Nantong Oncology Hospital between September 2020 and February 2022 were selected for the study.The 106 patients were divided into two groups with different interventions, 30 patients in the study group and 76 patients in the routine group. The patients in the study were treated with oral rivasaban for prophylactic anticoagulation, followed by postoperative limb massages and elastic socks in the conventional group. The incidence of venous thrombosis(VT) was analyzed, as well as the difference of coagulation index between the two groups before and after the intervention. Results The incidence of venous thrombosis was significantly lower in the study group(3.33%) than in the conventional group(11.84%), χ~2=1.822, P=0.177. After the intervention, the coagulation function indicators of the patients in the study group were significantly different from the control group, P<0.05. Conclusion Anticoagulation should be actively prevented in patients at high risk of tumor thrombosis in clinic, and anticoagulation with rivasabant can achieve both exogenous and endogenous anticoagulant effects, which can effectively reduce the risk of thrombosis.更多还原